Aligos Therapeutics Q3 2026 earnings

ALGS · 2026-11-06 08:00 BMO ET · 8-K on SEC · 10-Q on SEC

Cash burn slowed and licensing revenue increased, but net loss widened due to a large non-cash warrant loss.

Headline numbers

MetricActualYoYQoQ8-K location
EPS (GAAP)-$2.09+31.2%-14.9xEx. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $24.8M (+15.3% YoY)
  • One-offs in the quarter Change in fair value of 2023 common warrants: $0.2M income; Income tax provision: $0.3M
  • Effective tax rate -2.1% (prior-year -0.2%, year-to-date -8.1%)
  • Non-GAAP bridge No reconciliation provided in the release.

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$31.1M$30.4M$18.3M+2.3%
Total assets$47.2M$66.3M$88.5M-28.8%
Total stockholders' equity$11.3M$31.9M$53.5M-64.5%

Guidance

not stated in the 8-K

What drove it

  • Revenue story Revenue from customers increased 281% YoY to $2.8M, driven by a $39K licensing agreement revenue, compared to $741K in Q3 2025.
  • EPS story Net loss widened to $21.9M ($2.09 per share) from $31.5M ($3.04 per share) YoY, driven by a $4.2M loss on warrants and higher operating expenses.
  • One-off check Change in fair value of 2023 common warrants: $0.2M income (vs. $4.2M loss in Q3 2025).

The good

  • Cash burn slowed as R&D expenses decreased 21% YoY to $18.9M.
  • Revenue from customers increased 281% YoY to $2.8M.

The bad

  • Net loss widened to $21.9M ($2.09 per share) from $31.5M ($3.04 per share) YoY.
  • Total assets and stockholders' equity declined significantly YoY.

The ugly

  • Change in fair value of 2023 common warrants swung from a $4.2M loss to a $0.2M income, contributing to volatility in net loss.

Open questions

  • The release does not state the specific amount of the $3M milestone payment received in Q3 2026.
  • The release does not disclose the specific amount of the $25M upfront payment received in July 2026.
Full release

Aligos Therapeutics (ALGS) earnings release, November 6, 2026

Aligos Therapeutics, Inc. (ALGS) · Form 8-K, Item 2.02 · Filed · SEC filing

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2026.

“This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late Q3 2027,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout. We remain enthusiastic about pevifoscorvir sodium’s potential, as well as our ASO ALG-170675, which is currently in a Phase 1 study in China with our partner Amoytop. With these recent developments, we believe we are one step closer to our goal of bringing effective therapies to people living with chronic HBV infection.”

Recent Business Progress

Pipeline Updates

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection

The Phase 2 B-SUPREME study (NCT06963710) has completed enrollment with 131 participants enrolled in the HBeAg+ cohort (Part 1a) and 114 participants enrolled in the HBeAg- cohort (Part 2a).

Topline data for both the HBeAg+ and HBeAg- cohorts are expected in late Q3 2027.

ALG-170675: Potential best-in-class antisense oligonucleotide (ASO) for chronic hepatitis B virus (HBV) infection

Our partner Amoytop advanced ALG-170675 into Phase 1 clinical studies. Current costs for development in China are being funded by Amoytop, who maintain rights in Greater China.

Under our agreement with Amoytop, Aligos may utilize data from these studies for regulatory filings and other purposes. Each party is responsible for their own development costs.

Financial Results for the Three Months Ended September 30, 2026

Cash, cash equivalents and investments totaled $31.1 million as of September 30, 2026, compared with $77.8 million as of December 31, 2025. Our cash and cash equivalents are expected to provide sufficient funding of planned operations into the first quarter of 2027.

Net loss for the three months ended September 30, 2026 was $21.9 million or basic and diluted net loss per common share of $(2.09), compared to net loss of $31.5 million or basic and diluted net loss per common share of $(3.04), for the three months ended September 30, 2025.

Research and development (R&D) expenses for the three months ended September 30, 2026 were $18.9 million, compared with $23.9 million for the same period of 2025. The decrease was primarily due to an decrease in third-party expenses for the pevifoscorvir sodium Phase 2 clinical trial. Total R&D stock-based compensation expense incurred for the three months ended September 30, 2026 was $0.6 million, compared with $0.8 million for the same period of 2025.

General and administrative (G&A) expenses for the three months ended September 30, 2026 were $5.9 million, compared with $5.2 million for the same period of 2025. The increase in G&A expenses for this comparative period is primarily due to a increase in legal and other related expenses. Total G&A stock-based compensation expense incurred for the three months ended September 30, 2026 was $0.6 million, compared with $0.7 million for the same period of 2025.

Interest and other income, net, was income of $0.2 million for the three months ended September 30, 2026 compared with income of $1.1 million for the same period in 2025.

Change in fair value of 2023 common warrants for the three months ended September 30, 2026, was income of $0.2 million compared with a loss of $4.2 million for the same period of 2025.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statement

Financial statements

Income Statement

Aligos Therapeutics, Inc — jtarazi@aligos.com (In thousands, except share and per share amounts)

Aligos Therapeutics, Inc – Condensed Consolidated Statements of Operations – Three Months Ended – September 30, – 2026Aligos Therapeutics, Inc – Condensed Consolidated Statements of Operations – Three Months Ended – September 30, – 2025Aligos Therapeutics, Inc – Condensed Consolidated Statements of Operations – Nine Months Ended – September 30, – 2026Aligos Therapeutics, Inc – Condensed Consolidated Statements of Operations – Nine Months Ended – September 30, – 2025
Revenue from customers2,8307415,6602,017
Revenue from licensing agreements3927,817
Operating expenses:
Research and development18,89223,93766,29452,415
General and administrative5,8675,16517,89215,773
Total operating expenses24,75929,10284,18668,188
Loss from operations-21,890-28,361-50,709-66,171
Interest and other income, net1691,0851,2013,172
Change in fair value of 2023 common warrants187-4,2056,55858,971
Loss before income tax-21,534-31,481-42,950-4,028
Income tax provision-326-56-3,454-284
Net loss-21,860-31,537-46,404-4,312
Net loss per share, basic-2.09-3.04-4.45-0.44
Net loss per share, diluted-2.09-3.04-4.45-0.44
Weighted-average shares of common stock, basic10,461,95410,369,53510,432,1259,716,895
Weighted-average shares of common stock, diluted10,461,95410,369,53510,432,1259,716,895

Balance Sheet

jtarazi@aligos.com (in thousands)

September 30, 2026 – (Unaudited)December 31, 2025 – (Audited)(1)
Current assets:
Cash and cash equivalents31,09418,303
Short-term investments59,541
Other current assets3,5885,018
Total current assets34,68282,862
Other assets12,5075,671
Total assets47,18988,533
Liabilities and Stockholders’ Equity
Current liabilities19,60021,233
Other liabilities, noncurrent16,28313,755
Total liabilities35,88334,988
Total stockholders’ equity11,30653,545
Total liabilities and stockholders’ equity47,18988,533

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (In thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-46,404-4,312
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of discount on investments-491-1,744
Non-cash lease expense1,4121,383
Change in fair value of 2023 Common Warrants-6,560-58,971
Depreciation expense852673
Stock-based compensation including ESPP3,9603,586
Changes in operating assets and liabilities:
Accounts payable-7682,080
Accrued liabilities1,620-1,952
Operating lease liabilities-2,613-2,295
Other liabilities-47
Deferred revenue17
Other assets2,412777
Net cash and cash equivalents used in operating activities-46,627-60,758
Cash flows from investing activities:
Maturities of short-term investments60,00090,000
Purchase of short-term investments-125,460
Purchases of property and equipment-197-345
Net cash and cash equivalents provided by (used in) investing activities59,803-35,805
Cash flows from financing activities:
Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with 2025 PIPE offering, net of costs101,343
Payments on finance lease-86-11
Proceeds from the ESPP purchase236180

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements with respect to the expected timing of data readouts for the pevifoscorvir sodium B-SUPREME study; potential success of the Company’s development programs, including timing of the Company’s anticipated ASO clinical trials; statements regarding Amoytop’s success in developing the ASO and/or pevifoscorvir sodium in Greater China, including statements regarding timing and design of Amoytop’s anticipated clinical trials; and the company’s expectation that its cash, cash equivalents and investments provide sufficient funding of planned operations into the first quarter of 2027. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, reliance on collaborators to succeed in their development efforts and to comply with their contractual obligations, changes in the competitive landscape and the impact of global events and other macroeconomic conditions on Aligos’ business. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q to be filed with the Securities and Exchange Commission on November 6, 2026 and Aligos’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Investor Contact

Jordyn Tarazi

Vice President, Investor Relations & Corporate Communications

+1 (650) 910-0427 jtarazi@aligos.com

_____________________________________________

(1) The condensed consolidated balance sheet as of December 31, 2025 has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Aligos Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.